True Wealth Design LLC Has $29,000 Position in CVS Health Corporation $CVS

True Wealth Design LLC decreased its position in CVS Health Corporation (NYSE:CVS) by 61.5% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 417 shares of the pharmacy operator’s stock after selling 667 shares during the period. True Wealth Design LLC’s holdings in CVS Health were worth $29,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in CVS. Vanguard Group Inc. boosted its holdings in CVS Health by 0.8% during the first quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator’s stock worth $8,017,223,000 after purchasing an additional 969,027 shares during the last quarter. Dodge & Cox lifted its position in CVS Health by 4.8% during the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock worth $4,976,856,000 after buying an additional 3,353,223 shares in the last quarter. Invesco Ltd. boosted its stake in shares of CVS Health by 13.2% during the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock worth $1,383,039,000 after buying an additional 2,375,764 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of CVS Health by 14.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,309,289 shares of the pharmacy operator’s stock valued at $1,037,205,000 after acquiring an additional 1,942,886 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in CVS Health by 5.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator’s stock worth $924,643,000 after acquiring an additional 728,924 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on CVS shares. Barclays raised their price target on CVS Health from $80.00 to $87.00 and gave the company an “overweight” rating in a research note on Thursday, September 4th. Raymond James Financial raised their target price on shares of CVS Health from $75.00 to $90.00 in a research note on Friday, October 31st. The Goldman Sachs Group assumed coverage on shares of CVS Health in a research report on Tuesday, October 14th. They set a “buy” rating and a $91.00 price target on the stock. Sanford C. Bernstein lifted their price objective on shares of CVS Health from $72.00 to $77.00 and gave the company a “market perform” rating in a research report on Friday, September 5th. Finally, Zacks Research lowered CVS Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $89.45.

CVS Health Stock Up 0.4%

Shares of NYSE CVS opened at $79.00 on Friday. The stock has a market capitalization of $100.29 billion, a P/E ratio of 207.90, a PEG ratio of 0.87 and a beta of 0.60. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.83. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $85.15. The stock’s fifty day moving average is $77.15 and its 200 day moving average is $69.45.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, beating the consensus estimate of $1.36 by $0.24. The company had revenue of $102.87 billion during the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.09 EPS. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Sell-side analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend was Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is currently 700.00%.

Insider Activity

In related news, Director Anne A. Finucane sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the sale, the director directly owned 22,156 shares of the company’s stock, valued at $1,573,519.12. This trade represents a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 1.22% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.